Spruce Biosciences, Inc. (SPRB)

NASDAQ: SPRB · IEX Real-Time Price · USD
2.19
+0.04 (2.10%)
Mar 30, 2023, 12:46 PM EDT - Market open
2.1%
Market Cap 86.28M
Revenue (ttm) n/a
Net Income (ttm) -46.18M
Shares Out 39.75M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 25,852
Open 2.19
Previous Close 2.14
Day's Range 2.14 - 2.20
52-Week Range 0.96 - 3.57
Beta 2.33
Analysts Buy
Price Target 7.14 (+226.77%)
Earnings Date May 10, 2023

About SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 22
Stock Exchange NASDAQ
Ticker Symbol SPRB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for SPRB stock is "Buy." The 12-month stock price forecast is $7.14, which is an increase of 226.77% from the latest price.

Price Target
$7.14
(226.77% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for ra...

1 week ago - Business Wire

Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for ra...

1 month ago - Business Wire

Spruce Biosciences Announces $53.6 Million Private Placement Financing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocri...

1 month ago - Business Wire

Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endoc...

2 months ago - Business Wire

Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

2 months ago - Zacks Investment Research

Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endoc...

2 months ago - Business Wire

Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan

SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) and Kaken Pharmaceutical Co. Ltd (Tokyo Stock Exchange: 4521) today announced that the companies have en...

2 months ago - Business Wire

Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical ne...

4 months ago - Business Wire

Spruce Biosciences to Participate in November Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in November Investor Conferences

5 months ago - Business Wire

Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #Tildacerfont--Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

7 months ago - Business Wire

Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

8 months ago - Business Wire

Spruce Biosciences to Participate in June Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

10 months ago - Business Wire

Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

10 months ago - Business Wire

Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

11 months ago - Business Wire

Spruce Biosciences to Participate in May Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

11 months ago - Business Wire

Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C.

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

1 year ago - Business Wire

Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

1 year ago - Business Wire

Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

1 year ago - Business Wire

Spruce Biosciences to Participate in March Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

1 year ago - Business Wire

Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

1 year ago - Business Wire

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

1 year ago - Business Wire

Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders w...

1 year ago - Business Wire

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Other symbols: APTOCELUCNSPCYAD
1 year ago - Zacks Investment Research

Spruce Biosciences, Inc. (SPRB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agree...

1 year ago - Zacks Investment Research

Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference

1 year ago - Business Wire